(Q38156604)

29 August 2017

title

A review of tuberculosis: Focus on bedaquiline (English)

1 reference

29 August 2017

1 reference

Jack Brown

3

0 references

author name string

Bonnie Chan

series ordinal

1

1 reference

29 August 2017

Tina M Khadem

series ordinal

2

1 reference

29 August 2017

publication date

1 November 2013

1 reference

American Journal of Health-System Pharmacy

29 August 2017

published in

1 reference

29 August 2017

volume

70

1 reference

29 August 2017

issue

22

1 reference

29 August 2017

page(s)

1984-1994

1 reference

Is Mycobacterium tuberculosis 15,000 years old?

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

The history of tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

Evidence of spinal tuberculosis at the beginning of the fourth millennium BC from Arene Candide cave (Liguria, Italy).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

Detection and molecular characterization of 9,000-year-old Mycobacterium tuberculosis from a Neolithic settlement in the Eastern Mediterranean

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

31 March 2020

History of tuberculosis

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

Tuberculosis control and elimination 2010–50: cure, care, and social development

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

Interpreting the decline in tuberculosis: the role of secular trends in effective contact

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

Interpreting cell wall 'virulence factors' of Mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

Drug sensitivity and environmental adaptation of mycobacterial cell wall components.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

Mycobacterium tuberculosis inhibition of phagolysosome biogenesis and autophagy as a host defence mechanism

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

Epidemiology of resistant tuberculosis in Europe

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

Global incidence of multidrug-resistant tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

Molecular genetics of drug resistance in Mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

Why is long-term therapy required to cure tuberculosis?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

Randomized trials to optimize treatment of multidrug-resistant tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

Tuberculosis: the drug development pipeline at a glance

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

MDR-TB has new drug foe after fast-track approval

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

Unorthodox approach to the development of a new antituberculosis therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

Mycobacterium smegmatis and tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

In search of new cures for tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

TMC207: the first compound of a new class of potent anti-tuberculosis drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

Drug susceptibility testing in tuberculosis: A comparison of the proportion methods using Lowenstein-Jensen, middlebrook 7H10 and 7H11 agar media and a radiometric method

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

Colorimetric redox-indicator methods for the rapid detection of multidrug resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

M. tuberculosis persistence, latency, and drug tolerance

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130199

31 March 2020

Identifiers

DOI

10.2146/AJHP130199

1 reference

29 August 2017

1 reference